Scientists identify new therapeutic target for coronary heart disease

February 14, 2013

Scientists investigating how certain genes affect an individual's risk of developing coronary heart disease have identified a new therapeutic target, according to research published today in The American Journal of Human Genetics.

They have discovered that an enzyme known as ADAMTS7 plays a crucial role in the build-up of cells in the coronary arteries which lead to coronary heart disease.

Coronary heart disease (also known as ) is the nation's biggest killer, with around 94,000 deaths in the UK each year*. The condition happens when the blood supply to the heart is blocked by a build-up of – called atherosclerotic plaques – within the walls of one or more of the coronary arteries.

Lifestyle factors – including smoking, a bad diet and lack of exercise – contribute to an individual's risk of heart disease, but a number of genes have also been found to play a role.

The research was led by Shu Ye, Professor of and Genetics at Queen Mary, University of London. Professor Ye said: "Recent studies have identified a number of genetic regions that are associated with coronary heart disease. However, to translate these findings into new therapeutics which could benefit patients, we need to understand how these genetic variants are influencing the disease."

In this study the scientists focused on a genetic region associated with which contained the ADAMTS7 gene. This gene governs the production of an enzyme, also called ADAMTS7, which breaks down a structural protein called thrombospondin-5 in the arterial wall. This breakdown allows cells in the wall of the artery to move about more freely, and to migrate into the atherosclerotic plaques, making them larger and the affected artery narrower.

By analysing genetic data from an earlier study which involved 787 people in Italy, together with ultrasound scans of their arteries, the researchers found that a particular variant of the ADAMTS7 gene was associated with a 50 per cent reduction in risk of atherosclerosis.

Professor Ye said: "Through analysing arterial cells from 18 individuals, we found that this ADAMTS7 gene variant reduces the ability of the ADAMTS7 enzyme to break down the structural protein thrombospondin-5. As a result, arterial cells are less able to migrate and consequently we found that individuals carrying this genetic variant are less likely to develop atherosclerotic plaques and, even if they do, the plaques tend to be smaller.

"Further research is needed but this indicates that ADAMTS7 would be a promising target against which new medicines could be designed to act."

Explore further: New potential atherosclerosis risk marker discovered

More information: DOI: 10.1016/j.ajhg.2013.01.012

Related Stories

New potential atherosclerosis risk marker discovered

April 11, 2011
How your carotid artery moves can reveal your risk of a future heart attack, and it is now possible to study this vessel aspect in more detail thanks to a new technique which could eventually be used to identify patients ...

Recommended for you

Could aggressive blood pressure treatments lead to kidney damage?

July 18, 2017
Aggressive combination treatments for high blood pressure that are intended to protect the kidneys may actually be damaging the organs, new research from the University of Virginia School of Medicine suggests.

Quantifying effectiveness of treatment for irregular heartbeat

July 17, 2017
In a small proof-of-concept study, researchers at Johns Hopkins report a complex mathematical method to measure electrical communications within the heart can successfully predict the effectiveness of catheter ablation, the ...

Concerns over side effects of statins stopping stroke survivors taking medication

July 17, 2017
Negative media coverage of the side effects associated with taking statins, and patients' own experiences of taking the drugs, are among the reasons cited by stroke survivors and their carers for stopping taking potentially ...

Study discovers anticoagulant drugs are being prescribed against safety advice

July 17, 2017
A study by researchers at the University of Birmingham has shown that GPs are prescribing anticoagulants to patients with an irregular heartbeat against official safety advice.

Protein may protect against heart attack

July 14, 2017
DDK3 could be used as a new therapy to stop the build-up of fatty material inside the arteries

Heart study finds faulty link between biomarkers and clinical outcomes

July 14, 2017
Surrogate endpoints (biomarkers), which are routinely used in clinical research to test new drugs, should not be trusted as the ultimate measure to approve new health interventions in cardiovascular medicine, according to ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.